Evaluation of Exenatide Versus Insulin Glargine Treatment’s Impact on Brown Adipose Tissue Markers and Epicardial Adipose Tissue

Objective: Bone morphogenetic protein-7 (BMP7), unique uncoupling protein-1 (UCP1), PR domain containing 16 (PRDM-16), and irisin are important brown adipose tissue (BAT) markers.This study aimed to evaluate the effects of insulin glargine and exenatide treatment on BAT markers and epicardial adipose tissue (EAT) volume in patients with type 2 diabetes mellitus (T2DM). Methods:The study included 33 patients with T2DM.Patients with T2DM were randomized to the insulin glargine and exenatide arms.Before and 24 weeks after treatment, serum BAT markers and EAT levels were evaluated and compared in both treatment arms.Results: EAT decreased in both groups with treatments (both groups p<0.001), but there was no significant difference between the two groups when compared.BMP7 significantly decreased with exenatide treatment (p=0.03).UCP1 significantly decreased with insulin glargine treatment (p=0.008).Pre-and post-treatment percentage changes in irisin, BMP7, UCP1, and PRDM-16 were similiar. Conclusion:Weight loss and a decrease body fat mass occur with exenatide treatment, but this is probably unrelated to BAT activation.